MetaCap

Ocular Therapeutix Inc. (OCUL)

NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD

5.57-0.29 (-4.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OCUL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.44
52-week range
5.54 – 16.44
Day range
5.54 – 5.95
Volume / Avg
2.89M / 3.03M
Beta
—

52-week range

$5.54$16.44

OCUL stock today

Ocular Therapeutix (OCUL) closed at $5.57 on Nov 20, down 4.95% (-$0.29), versus the S&P 500's 3.70% decline. Shares are 66.1% below their 52-week high of $16.44, set on Dec 8, 2025 and 0.5% above the 52-week low of $5.54, near the bottom of the past year's range. OCUL is down 54.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.5%.

Ocular Therapeutix has posted a net loss over the last twelve months (EPS of -$1.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Ocular Therapeutix

Company profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Pravin U. Dugel M.D.
Headquarters
Bedford, MA
Employees
325
IPO year
2014
Website
ocutx.com

Financial highlights

Full financials

In fiscal 2025, Ocular Therapeutix generated $52.0 million in revenue, down 18.5% from fiscal 2024, the first decline in the 14 years shown. Ocular Therapeutix reported a net loss of $265.9 million, compared with a loss of $193.5 million a year earlier. Gross margin was 87.3% (down from 91.2%) and operating margin -519.8%.

Ocular Therapeutix annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$51.95M$63.72M$58.44M$51.49M$43.52M
Growth-18.47%+9.03%+13.49%+18.32%+150.08%
Net income$-265.94M$-193.51M$-80.74M$-71.04M$-6.55M
EPS (diluted)$-1.42$-1.22$-1.02$-0.97$-0.98

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$25.73+361.94%

  • Strong buy 4
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $14.00High $34.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.37 vs $-0.36
Surprise
-2.78%

OCUL news

All OCUL news

Ocular Therapeutix peers

Health Care sector
OCUL peer companies
CompanyPrice% ChgMarket capCompare
GENBGenerate Biomedicines Inc.9.54-8.00%$1.23Bvs OCUL
SLNSilence Therapeutics Plc American Depository Share19.810.00%$1.23Bvs OCUL
MNKDMannKind Corporation3.85-2.53%$1.24Bvs OCUL
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs OCUL
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs OCUL
GHRSGH Research PLC17.53-5.55%$1.20Bvs OCUL
LBRXLB Pharmaceuticals Inc38.85-2.97%$1.26Bvs OCUL
AVLNAvalyn Pharma Inc.28.40-1.05%$1.26Bvs OCUL

Indexes, lists and sector

Ocular Therapeutix stock FAQ

What is Ocular Therapeutix's stock price today?

OCUL last traded at $5.57 as of Nov 20, 4:00 PM EST, down 4.95% on the day. Prices are delayed at least 15 minutes.

Who is Ocular Therapeutix's CEO?

Dr. Pravin U. Dugel M.D. is the chief executive officer of Ocular Therapeutix Inc., which has about 325 employees.

What is the OCUL 52-week high?

The 52-week high for OCUL is $16.44 and the 52-week low is $5.54. The stock is currently 66.1% below its high.

Compare OCUL